Mark R. Denison
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Mark R. Denison (born May 13, 1955)[1] is the Stahlman Professor of Pediatrics, Pathology, Microbiology & Immunology and director of the Division of Pediatric Infectious Diseases at Vanderbilt University Medical Center. Denison has been researching the replication, pathogenesis and evolution of coronaviruses for over 30 years, and has published his research on SARS-CoV, MERS-CoV, and the current SARS-CoV-2.[2]
Education and career
[edit]Denison obtained a B.A. in Chemistry and English in 1977 from the University of Kansas and an M.D. in 1980 from the University of Kansas School of Medicine.[3]
Denison led the team that developed the remdesivir drug to treat COVID-19.[4]
In 2011 he was elected a Fellow of the American Association for the Advancement of Science.[5]
References
[edit]- ^ "Mark R. Denison". United States Public Records (via familysearch.org).
- ^ "Mark Denison, MD | Vanderbilt Institute for Global Health". www.vumc.org.
- ^ "Mark R. Denison". ORCID (Open Researcher and Contributor ID).
- ^ "Coronavirus - How to beat the next pandemic". Retrieved 19 March 2022.
- ^ "Historic Fellows". American Association for the Advancement of Science.
External links
[edit]- Mark R. Denison publications indexed by Google Scholar
| Authority control databases: Academics |
|---|
 | This biography of an academic is a stub. You can help Wikipedia by expanding it. |